Sermorelin (GRF 1-29) is a peptide made up of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It is a growth hormone secretagogue, meaning it prompts the pituitary gland to release the body's own growth hormone rather than supplying growth hormone directly.

What does research suggest about Sermorelin?

Animal studies document that sermorelin stimulates growth hormone release from the pituitary, and it has a history of clinical use in diagnostic and therapeutic settings. However, modern human evidence for the anti-aging, recovery, and performance uses commonly discussed online is limited, and research-market use is not a validated therapy.

Is Sermorelin approved or legal?

Sermorelin was previously marketed as a medicine for diagnostic and therapeutic use, but its availability and regulatory status vary by country. Research-market supply is not equivalent to an approved pharmaceutical, so legal standing should be checked against local regulations.

Is Sermorelin safe, and what are the side effects?

Because sermorelin acts on the growth hormone axis, its effects are hormonal and carry real risks that make medical supervision important. Reported side effects include injection-site reactions and flushing. Long-term safety of research-market material is not well characterized.

How does Sermorelin compare to CJC-1295?

Both are GHRH-based growth hormone secretagogues that stimulate pituitary growth hormone release. Sermorelin is the native GRF 1-29 fragment with a short half-life, whereas CJC-1295 is engineered for a longer duration of action. This page is educational and does not recommend either compound.

Does Sermorelin directly contain growth hormone?

No. Sermorelin does not contain or supply growth hormone. It is a GHRH analog that signals the pituitary gland to release the body's own growth hormone in a pulsatile pattern resembling natural physiology.

How does Sermorelin differ from directly using growth hormone?

Sermorelin is a GHRH fragment (the first 29 amino acids of growth-hormone-releasing hormone). Rather than being growth hormone itself, it signals the pituitary to release the body's own GH, so its effect depends on an intact, responsive pituitary. In principle this keeps some natural feedback regulation in the loop, which is a key conceptual distinction people draw versus injecting GH directly. This is background biology, not a claim of safety or benefit.

Why is Sermorelin often mentioned alongside CJC-1295?

Both are GHRH-based growth-hormone secretagogues, so they come up in the same discussions. The commonly cited contrast is duration: sermorelin is a short-acting GHRH fragment with a very brief presence in the body, whereas CJC-1295 was designed with modifications intended to extend its action. People compare them on that pharmacological basis, but this is educational context only, not a recommendation or protocol.

Is Sermorelin a modern discovery or an older compound?

It is an older compound, not a new one. It traces back to research on growth-hormone-releasing hormone in the early 1980s and was an actual marketed prescription medicine in the 1990s before the branded product was later discontinued. Its current prominence in the research and compounding market is more of a resurgence of an established peptide than the debut of a novel one.

Where can I buy Sermorelin and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Growth Hormone Secretagogue

Buy Sermorelin – Vendors, Prices, Testing and Evidence

Buy Sermorelin

Also known as: GRF 1-29

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A GHRH fragment historically used clinically, now common in research and compounding contexts.

Where can you buy Sermorelin?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Sermorelin is a peptide corresponding to the first 29 amino acids of GHRH.

What is not established?

Some historical clinical use; modern research-market use is not a validated therapy.

Safety

Hormonal effects carry real risks; supervision matters for anything affecting the GH axis.

Regulatory status

Previously marketed as a medicine for diagnostic/therapeutic use; availability and status vary by country.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Sermorelin: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Sermorelin research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Sermorelin research product

Code PEPTIDES10 −10% · discount code details

What is it?

Sermorelin is a peptide corresponding to the first 29 amino acids of GHRH.

Research and evidence

Sermorelin, also known as GRF 1-29, is a peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone (GHRH) — the fragment that carries GHRH's full biological activity. As a growth hormone secretagogue, it is designed to act on the pituitary gland rather than to supply growth hormone directly. By binding pituitary GHRH receptors, sermorelin stimulates the gland to release the body's own growth hormone in a pulsatile pattern that resembles natural physiology. This mechanism-based distinction — prompting endogenous release rather than replacing the hormone — is the central reason sermorelin has attracted both historical clinical interest and ongoing attention in research and compounding contexts.

The evidence picture is best understood in layers. In animal studies, sermorelin's ability to trigger growth hormone release from the pituitary is well documented, and it was historically studied and marketed as a medicine for diagnostic and therapeutic use, including in the assessment of growth hormone secretion. That clinical history is real but does not translate into validation of the material sold today on the research market, which is not an approved therapy in most jurisdictions. Human data supporting the physique, anti-aging, recovery, or performance uses commonly discussed online is limited, and much of what circulates is mechanistic reasoning or anecdote rather than controlled clinical evidence. peptides.cx assigns sermorelin an evidence grade of C, reflecting documented biological activity alongside a shortage of modern, high-quality human trials for the applications people most often search for.

Because sermorelin acts on the growth hormone axis, its effects are genuinely hormonal, and that carries real considerations. Reported side effects include injection-site reactions and flushing, and any intervention that modulates growth hormone signaling warrants medical supervision. Its regulatory status varies by country: it was previously marketed as a medicine, but availability and legal standing differ from one jurisdiction to another, and research-market supply is not equivalent to a licensed pharmaceutical. Sermorelin is frequently compared with CJC-1295 and other GHRH analogs; this reference exists to help you understand what the science does and does not currently show. It is educational information only, not medical advice, and does not include dosing, protocols, or sourcing guidance.

Evidence grade: C

Some historical clinical use; modern research-market use is not a validated therapy. GH-release effects documented.

Human evidence

Some historical clinical use; modern research-market use is not a validated therapy.

Animal and preclinical evidence

GH-release effects documented.

Proposed mechanisms

Stimulates pituitary growth-hormone release

Safety concerns and known side effects

Hormonal effects carry real risks; supervision matters for anything affecting the GH axis.

Injection-site reactions
Flushing reported

Regulatory status

Previously marketed as a medicine for diagnostic/therapeutic use; availability and status vary by country.

Sermorelin research timeline

early 1980s
Following the isolation of growth-hormone-releasing hormone (GHRH), researchers identified that a truncated fragment of its first 29 amino acids retained the full GH-releasing activity of the parent hormone.
1980s
This 1-29 fragment was developed as a synthetic peptide (sermorelin) and characterized in preclinical and early human pharmacology as a way to probe pituitary function.
1990s
Sermorelin was marketed as a prescription medicine (e.g. under the Geref brand) and used clinically as a diagnostic agent to assess pituitary GH reserve and, in some settings, in pediatric growth studies.
late 2000s
The branded pharmaceutical product was discontinued in the U.S. market, leaving no widely available FDA-approved sermorelin drug and shifting the compound toward compounding-pharmacy and research contexts.
2010s
Interest resurged through compounding pharmacies and the research/wellness market, where sermorelin was discussed as a GHRH-based alternative to direct growth-hormone use; rigorous modern outcome trials remained limited.
early 2020s
Regulatory attention to compounded peptides increased, and availability and legal status of sermorelin continued to vary by country, with much current online use falling outside validated therapeutic contexts.

Frequently asked questions about Sermorelin

What is Sermorelin?: Sermorelin (GRF 1-29) is a peptide made up of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It is a growth hormone secretagogue, meaning it prompts the pituitary gland to release the body's own growth hormone rather than supplying growth hormone directly.
What does research suggest about Sermorelin?: Animal studies document that sermorelin stimulates growth hormone release from the pituitary, and it has a history of clinical use in diagnostic and therapeutic settings. However, modern human evidence for the anti-aging, recovery, and performance uses commonly discussed online is limited, and research-market use is not a validated therapy.
Is Sermorelin approved or legal?: Sermorelin was previously marketed as a medicine for diagnostic and therapeutic use, but its availability and regulatory status vary by country. Research-market supply is not equivalent to an approved pharmaceutical, so legal standing should be checked against local regulations.
Is Sermorelin safe, and what are the side effects?: Because sermorelin acts on the growth hormone axis, its effects are hormonal and carry real risks that make medical supervision important. Reported side effects include injection-site reactions and flushing. Long-term safety of research-market material is not well characterized.
How does Sermorelin compare to CJC-1295?: Both are GHRH-based growth hormone secretagogues that stimulate pituitary growth hormone release. Sermorelin is the native GRF 1-29 fragment with a short half-life, whereas CJC-1295 is engineered for a longer duration of action. This page is educational and does not recommend either compound.
Does Sermorelin directly contain growth hormone?: No. Sermorelin does not contain or supply growth hormone. It is a GHRH analog that signals the pituitary gland to release the body's own growth hormone in a pulsatile pattern resembling natural physiology.
How does Sermorelin differ from directly using growth hormone?: Sermorelin is a GHRH fragment (the first 29 amino acids of growth-hormone-releasing hormone). Rather than being growth hormone itself, it signals the pituitary to release the body's own GH, so its effect depends on an intact, responsive pituitary. In principle this keeps some natural feedback regulation in the loop, which is a key conceptual distinction people draw versus injecting GH directly. This is background biology, not a claim of safety or benefit.
Why is Sermorelin often mentioned alongside CJC-1295?: Both are GHRH-based growth-hormone secretagogues, so they come up in the same discussions. The commonly cited contrast is duration: sermorelin is a short-acting GHRH fragment with a very brief presence in the body, whereas CJC-1295 was designed with modifications intended to extend its action. People compare them on that pharmacological basis, but this is educational context only, not a recommendation or protocol.
Is Sermorelin a modern discovery or an older compound?: It is an older compound, not a new one. It traces back to research on growth-hormone-releasing hormone in the early 1980s and was an actual marketed prescription medicine in the 1990s before the branded product was later discontinued. Its current prominence in the research and compounding market is more of a resurgence of an established peptide than the debut of a novel one.
Where can I buy Sermorelin and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

GH axisComparison with CJC-1295

Compare Sermorelin

Sermorelin vs CJC-1295 Sermorelin vs Tesamorelin

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10